A Phase 1 interventional study of Mirdametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany. Not yet recruiting at 1 site in Germany. Open to participants aged 0 Months to 21 Months. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the safety, pharmacokinetic (PK), and tolerability of multiple treatment cycles of oral mirdametinib in infants and toddlers (0 to less than [\<] 24 months of age) with measurable neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PNs) that is symptomatic or asymptomatic but in a high-risk location with a high risk of morbidity.
63 studies on the registry are indexed under Neurofibroma, Plexiform; 19 are open to participants now.
This study's planned enrollment of 6 is below the median of 36 across 43 interventional studies indexed under Neurofibroma, Plexiform.
Browse Neurofibroma, Plexiform studies →SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany is the lead sponsor of 14 studies on the registry; 6 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
4.1. Asymptomatic: Participant has a measurable NF1 PN in a high risk location with a high risk of morbidity.
A high-risk location with a high risk of morbidity is defined as:
Adjacent to high-risk structure(s), defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant receives 0.5 milligram (mg) twice daily.
Drug: Mirdametinib
Participants receives 0.25 mg twice daily.
Drug: Mirdametinib
Mirdametinib dispersible tablet administered orally.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to approximately 6 years
Number of Participants With Clinically Significant Changes in Laboratory Parameters, Vital Signs, Physical Examination Findings and Electrocardiograms (ECGs), Echocardiogram (ECHO), and Ophthalmic Exam Findings
Time frame: Up to approximately 6 years
Number of Participants With Severity of Adverse Events (AEs) According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
Time frame: Up to approximately 6 years
Minimum Observed Concentration (Cmin) of Mirdametinib
Time frame: Cycle 1 Days 1 and 15: pre-dose and post-dose at 1 and 4 hours; Cycles 2, 4 and 8 Day 15: Pre-dose and post-dose at 1 hour (each cycle = 28 days)
Maximum Observed Concentration (Cmax) of Mirdametinib
Time frame: Cycle 1 Days 1 and 15: pre-dose and post-dose at 1 and 4 hours; Cycles 2, 4 and 8 Day 15: Pre-dose and post-dose at 1 hour (each cycle = 28 days)
Area Under the Concentration-time Curve (AUC) at Steady State for Mirdametinib
Time frame: Cycle 1 Days 1 and 15: pre-dose and post-dose at 1 and 4 hours; Cycles 2, 4 and 8 Day 15: Pre-dose and post-dose at 1 hour (each cycle = 28 days)
Confirmed Objective Response Rate (ORR)
Confirmed ORR is defined as plexiform neurofibroma (PN) decrease greater than or equal to (\>=) 20 percent (%) compared to baseline in consecutive scans within 2 to 6 months) using centrally read magnetic resonance imaging (MRI) volumetric analyses by a Blinded Independent Central Review (BICR).
Time frame: Up to approximately 6 years
Duration of Response (DoR)
DoR is defined as the time from onset of confirmed complete response (CR) + partial response (PR) using centrally read MRI volumetric analysis by a BICR to the earliest event of progressive disease (PD) or death.
Time frame: Up to approximately 6 years
Change From Baseline in Quality of Life (QoL) Assessed by the age-specific Pediatric Quality of Life Inventory (PedsQL) Infant Scales
The PedsQL Infant Scales are multidimensional parent-proxy-report scales designed to assess health-related quality of life in infants from 1 to 24 months of age over the past 7 days. The Infant Scales consists of 36 items in the 1- to 12-month form and 45 items in the 13- to 24-month form, with 5 dimensions: physical functioning, physical symptoms, emotional functioning, social functioning, and cognitive functioning.
Time frame: Baseline up to approximately 6 years
Change From Baseline Pain Assessment by Age-specific Pain Scale: Faces, Legs, Activity, Cry, Consolability (FLACC)
FLACC is a behavioural pain assessment scale used by the investigator for nonverbal or preverbal patients who are unable to self-report their level of pain. Pain is assessed in infants and children from 2 months to 7 years of age through observation of 5 categories, including face, legs, activity, cry, and consolability. The total score for FLACC scale ranges from 0 to 10, with each category scored on a scale of 0 to 2.
Time frame: Baseline up to approximately 6 years
Plan to share: No — IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.
Start is estimated for Dec 2026; primary completion for Oct 2032, 70 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirdametinib
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany →